Recent Company News

• 07:50 AM ET Mar 19, 2026
  

  Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

• 09:10 AM ET Mar 17, 2026
  

  InvestorNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Nasdaq Notice on Minimum Bid Price Compliance

• 04:05 PM ET Mar 16, 2026
  

  Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

• 01:08 PM ET Mar 02, 2026
  

  BioMedNewsBreaks - Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Expanded IIA Grant Support for Robotic Aseptic Fill & Finish Platform

• 09:19 AM ET Mar 02, 2026
  

  Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised EUR 12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

• 08:12 AM ET Feb 25, 2026
  

  Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

• 07:00 AM ET Feb 17, 2026
  

  Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

• 07:10 AM ET Jul 23, 2024
  

  Scinai Immunotherapeutics announces Positive Regulatory Feedback from PEI on path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb ($4.31, 0.00)